Dual-functionalized liposome by co-delivery of paclitaxel with sorafenib for synergistic antitumor efficacy and reversion of multidrug resistance
Multidrug resistance (MDR) remains one of the major reasons for inefficiency of many chemotherapeutic agents in cancer therapy. In this study, a D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) and polylysine-deoxycholic acid copolymer (PLL-DA) co-modified cationic liposome coating with hyal...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2019-01-01
|
| Series: | Drug Delivery |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/10717544.2019.1580797 |
| _version_ | 1828918585492242432 |
|---|---|
| author | Meng Lei Guanglan Ma Sijia Sha Xueyuan Wang Haiting Feng Yongqiang Zhu Xiao Du |
| author_facet | Meng Lei Guanglan Ma Sijia Sha Xueyuan Wang Haiting Feng Yongqiang Zhu Xiao Du |
| author_sort | Meng Lei |
| collection | DOAJ |
| description | Multidrug resistance (MDR) remains one of the major reasons for inefficiency of many chemotherapeutic agents in cancer therapy. In this study, a D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) and polylysine-deoxycholic acid copolymer (PLL-DA) co-modified cationic liposome coating with hyaluronic acid (HA) was constructed for co-delivery of paclitaxel (PTX) and chemosensitizing agent, sorafenib (SOR) to treat the MDR cancer. The multifunctional liposome (HA-TPD-CL-PTX/SOR) presented good stability against rat plasma and was capable of reversing surface zeta potential under acidic conditions in the presence of HAase. Additionally, experimental result confirmed that the PLL-DA copolymer would facilitate the endo-lysosomal escape of the liposome. In vitro study demonstrated that HA-TPD-CL-PTX/SOR could significantly enhance drug accumulation in resistant MCF-7/MDR cells by inhibiting the P-gp efflux, and effectively inhibited growth of tumor cells. Furthermore, the liposome showed an enhanced anticancer activity in vivo, with a tumor growth inhibition rate of 78.52%. In summary, HA-TPD-CL-PTX/SOR exhibited a great potential for effective therapy of resistant cancers by combining with chemotherapeutic agents and could be a promising nano-carrier for reversing MDR and improving the effectiveness of chemotherapy. |
| first_indexed | 2024-12-13T21:12:57Z |
| format | Article |
| id | doaj.art-245476cbf18f4a8c8de863f58563724b |
| institution | Directory Open Access Journal |
| issn | 1071-7544 1521-0464 |
| language | English |
| last_indexed | 2024-12-13T21:12:57Z |
| publishDate | 2019-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Drug Delivery |
| spelling | doaj.art-245476cbf18f4a8c8de863f58563724b2022-12-21T23:31:19ZengTaylor & Francis GroupDrug Delivery1071-75441521-04642019-01-0126126227210.1080/10717544.2019.15807971580797Dual-functionalized liposome by co-delivery of paclitaxel with sorafenib for synergistic antitumor efficacy and reversion of multidrug resistanceMeng Lei0Guanglan Ma1Sijia Sha2Xueyuan Wang3Haiting Feng4Yongqiang Zhu5Xiao Du6College of Science, Nanjing Forestry UniversityCollege of Life Science, Nanjing Normal UniversityCollege of Science, Nanjing Forestry UniversityCollege of Life Science, Nanjing Normal UniversityCollege of Life Science, Nanjing Normal UniversityCollege of Life Science, Nanjing Normal UniversityCollege of Life Science, Nanjing Normal UniversityMultidrug resistance (MDR) remains one of the major reasons for inefficiency of many chemotherapeutic agents in cancer therapy. In this study, a D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) and polylysine-deoxycholic acid copolymer (PLL-DA) co-modified cationic liposome coating with hyaluronic acid (HA) was constructed for co-delivery of paclitaxel (PTX) and chemosensitizing agent, sorafenib (SOR) to treat the MDR cancer. The multifunctional liposome (HA-TPD-CL-PTX/SOR) presented good stability against rat plasma and was capable of reversing surface zeta potential under acidic conditions in the presence of HAase. Additionally, experimental result confirmed that the PLL-DA copolymer would facilitate the endo-lysosomal escape of the liposome. In vitro study demonstrated that HA-TPD-CL-PTX/SOR could significantly enhance drug accumulation in resistant MCF-7/MDR cells by inhibiting the P-gp efflux, and effectively inhibited growth of tumor cells. Furthermore, the liposome showed an enhanced anticancer activity in vivo, with a tumor growth inhibition rate of 78.52%. In summary, HA-TPD-CL-PTX/SOR exhibited a great potential for effective therapy of resistant cancers by combining with chemotherapeutic agents and could be a promising nano-carrier for reversing MDR and improving the effectiveness of chemotherapy.http://dx.doi.org/10.1080/10717544.2019.1580797multidrug resistanceliposomecombination therapytumor targeting capabilitynanomedicine |
| spellingShingle | Meng Lei Guanglan Ma Sijia Sha Xueyuan Wang Haiting Feng Yongqiang Zhu Xiao Du Dual-functionalized liposome by co-delivery of paclitaxel with sorafenib for synergistic antitumor efficacy and reversion of multidrug resistance Drug Delivery multidrug resistance liposome combination therapy tumor targeting capability nanomedicine |
| title | Dual-functionalized liposome by co-delivery of paclitaxel with sorafenib for synergistic antitumor efficacy and reversion of multidrug resistance |
| title_full | Dual-functionalized liposome by co-delivery of paclitaxel with sorafenib for synergistic antitumor efficacy and reversion of multidrug resistance |
| title_fullStr | Dual-functionalized liposome by co-delivery of paclitaxel with sorafenib for synergistic antitumor efficacy and reversion of multidrug resistance |
| title_full_unstemmed | Dual-functionalized liposome by co-delivery of paclitaxel with sorafenib for synergistic antitumor efficacy and reversion of multidrug resistance |
| title_short | Dual-functionalized liposome by co-delivery of paclitaxel with sorafenib for synergistic antitumor efficacy and reversion of multidrug resistance |
| title_sort | dual functionalized liposome by co delivery of paclitaxel with sorafenib for synergistic antitumor efficacy and reversion of multidrug resistance |
| topic | multidrug resistance liposome combination therapy tumor targeting capability nanomedicine |
| url | http://dx.doi.org/10.1080/10717544.2019.1580797 |
| work_keys_str_mv | AT menglei dualfunctionalizedliposomebycodeliveryofpaclitaxelwithsorafenibforsynergisticantitumorefficacyandreversionofmultidrugresistance AT guanglanma dualfunctionalizedliposomebycodeliveryofpaclitaxelwithsorafenibforsynergisticantitumorefficacyandreversionofmultidrugresistance AT sijiasha dualfunctionalizedliposomebycodeliveryofpaclitaxelwithsorafenibforsynergisticantitumorefficacyandreversionofmultidrugresistance AT xueyuanwang dualfunctionalizedliposomebycodeliveryofpaclitaxelwithsorafenibforsynergisticantitumorefficacyandreversionofmultidrugresistance AT haitingfeng dualfunctionalizedliposomebycodeliveryofpaclitaxelwithsorafenibforsynergisticantitumorefficacyandreversionofmultidrugresistance AT yongqiangzhu dualfunctionalizedliposomebycodeliveryofpaclitaxelwithsorafenibforsynergisticantitumorefficacyandreversionofmultidrugresistance AT xiaodu dualfunctionalizedliposomebycodeliveryofpaclitaxelwithsorafenibforsynergisticantitumorefficacyandreversionofmultidrugresistance |